Epidermal cell proliferation and promoting ability of phorbol esters

Thomas J. Slaga, Aurora Viaje

Research output: Contribution to journalArticle

74 Scopus citations

Abstract

Dose-response relationships on the abilities of several phorbol ester tumor promoters to promote skin tumors after 7, 12-dimethylbenz[a]anthracene initiation and to bring about edema, inflammation, and epidermal hyperplasia were determined in female Charles River CD-1 mice. The promoting ability of the potent synthetic promoter, phorbol-12, 13-dioctanoate (PdiC8), was determined over a dose range of 0.1-10 μg/application. Administration of PdiC8 two times weekly at dosages of 4, 6, 8, and 10 μ gave little variation in tumor response. A dose-dependent tumor response occurred at doses of 1-4 μg PdiC8. Only 1 papilloma was observed when PdiC8 was given twice weekly at a dose of 0.1 or 0.5 μg. A similar dose-response relation was observed for the ability of PdiC8 to stimulate epidermal hyperplasia. Investigations of other phorbol esters revealed an excellent correlation between their promoting ability and their ability to induce epidermal hyperplasia; however, that was not the case for compounds outside the phorbol ester series (i.e., acetic acid, cantharidin, and ethylphenylpropiolate).

Original languageEnglish (US)
Pages (from-to)1145-1149
Number of pages5
JournalJournal of the National Cancer Institute
Volume57
Issue number5
DOIs
Publication statusPublished - Nov 1976

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this